Impact of specialist management on survival from radiation‐associated angiosarcoma of the breast. BJS 2018; 105: 401-409.
Published: 6th February 2018
Authors: L. Feinberg, A. Srinivasan, J. K. Singh, M. Parry, J. Stevenson, L. Jeys et al.
Radiation‐associated angiosarcoma of the breast (RAAS) is a rare complication of adjuvant radiotherapy associated with poor survival. The British Sarcoma Group guidelines recommend that all angiosarcomas are referred to a sarcoma multidisciplinary team, although there is no recommendation that patients are managed within a sarcoma service. The aims of this study were to compare survival, complete excision rates and local recurrence rates of patients managed within a sarcoma service and those managed within local hospitals.
All patients with RAAS referred to a regional sarcoma service between 1998 and 2015 were identified from prospective databases. Patient records, and radiology, pathology and operation notes were reviewed retrospectively.
Thirty‐six patients were operated on with curative intent; 26 were managed by the sarcoma service (of whom 21 underwent radical excision of the irradiated field followed by chest wall reconstruction) and ten were managed locally. Median age was 69·5 (range 43–85) years. Disease‐specific survival was significantly longer in patients managed by the sarcoma service than in those managed locally: median 91·1 (range 69·2–113·0)
Specialist management of RAAS leads to fewer local recurrences and improved disease‐specific survival. Early referral and management within specialist units is recommended.Full text
You may also be interested in
Risk of recurrence and death in patients with breast cancer after delayed deep inferior epigastric perforator flap reconstruction.
Authors: H. Adam, A. C. Docherty Skogh, Å. Edsander Nord, I. Schultz, J. Gahm, P. Hall et al.
Notes: DIEP is safe
Predictors of complications after direct‐to‐implant breast reconstruction with an acellular dermal matrix from a multicentre randomized clinical trial.
Authors: V. L. Negenborn, R. E. G. Dikmans, M. B. Bouman, H. A. H. Winters, J. W. R. Twisk, P. Q. Ruhé et al.
Notes: Not good for large breast
Population‐based study of the sensitivity of axillary ultrasound imaging in the preoperative staging of node‐positive invasive lobular carcinoma of the breast.
Authors: E. Morrow, A. Lannigan, J. Doughty, J. Litherland, J. Mansell, S. Stallard et al.
Notes: Less sensitive in ILC
Routine histopathological examination after female‐to‐male gender‐confirming mastectomy. BJS 2018; 105: 885-892.
Authors: S. M. J. Van Renterghem, J. Van Dorpe, S. J. Monstrey, J. Defreyne, K. E. Y. Claes, M. Praet et al.
Notes: The case for
Meta‐analysis of neoadjuvant therapy and its impact in facilitating breast conservation in operable breast cancer. BJS 2018; 105: 469-481.
Authors: A. Karakatsanis, M. K. Tasoulis, F. Wärnberg, G. Nilsson, F. MacNeill
Notes: Still unnecessary mastectomies
Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non‐surgical management of triple‐negative breast cancer. BJS 2018; 105: 535-543.
Authors: R. F. D. van la Parra, A. B. Tadros, C. M. Checka, G. M. Rauch, A. Lucci, B. D. Smith et al.
Notes: Ductal carcinoma in situ and microcalcification important
Authors: Z. E. Winters, J. R. Benson
Authors: P. McAnena, A. Lowery, M. J. Kerin
Notes: Promising technology
Minimizing inequality in access to precision medicine in breast cancer by real‐time population‐based molecular analysis in the SCAN‐B initiative. BJS 2018; 105: e158-e168.
Authors: L. Rydén, N. Loman, C. Larsson, C. Hegardt, J. Vallon‐Christersson, M. Malmberg et al.
Notes: Promising Swedish initiative
Authors: M. A. Stammes, S. L. Bugby, T. Porta, K. Pierzchalski, T. Devling, C. Otto et al.
Notes: Visible results
MiR‐128 regulation of glucose metabolism and cell proliferation in triple‐negative breast cancer. BJS 2018; 105: 75-85.
Authors: M. Xiao, C. Lou, H. Xiao, Y. Yang, X. Cai, C. Li et al.
Notes: New molecular target?
International validation of the European Organisation for Research and Treatment of Cancer QLQ‐BRECON23 quality‐of‐life questionnaire for women undergoing breast reconstruction. BJS 2018; 105: 209-222.
Authors: Z. E. Winters, M. Afzal, C. Rutherford, B. Holzner, G. Rumpold, R. A. da Costa Vieira et al.
Notes: Useful tool